Biote Corp. (BTMD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.53% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ...
- biote Q2 Earnings Call Highlights
- biote Q1 Earnings Call Highlights
- biote Corp. Q1 2026 Earnings Call Summary
- biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
- How The Investment Story For Biote (BTMD) Is Shifting With Reset Expectations And 2026 Guidance
- Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
- biote Corp. (BTMD) Reports Break-Even Earnings for Q2
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Biote Corp..
Full BTMD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.